Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Switching From Tenofovir Disoproxil Fumarate-based Antiretroviral Therapy Regimens to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virally Suppressed Adults With HIV-1 Infection

NCT05122754 is registered in ClinicalTrials.gov with Shanghai Public Health Clinical Center as lead sponsor.

NCT NCT05122754
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05122754 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Switching From Tenofovir Disoproxil Fumarate-based Antiretroviral Therapy Regimens to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virally Suppressed Adults With HIV-1 Infection
Lead sponsor
Shanghai Public Health Clinical Center
Phase
Phase 4
Overall status
Unknown status
Start date
December 8, 2021
Completion date
April 28, 2024
Enrollment
150 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1-infection